HELP Cybin Inc.
Company Analysis
Latest News
🟢 Cybin is trading 6.3% up today on broader risk-on sentiment
Cybin is trading at $8.10 (+6.3%) in pre-market, rebounding after a weak close at $7.62 on July 24. • The move appears aligned with stronger U.S. futures and...
🟢 Cybin is trading 10.1% up
Cybin is trading at $7.83, up 10.1% from a comparison close of $7.11 during regular trading. This is a price-action follow-up, so a separate catalyst may not...
🟢 Cybin is trading 8.6% up today on Phase 3 trial progress and $50M equity raise
Cybin is trading at $7.72 (+8.58%) following fresh momentum around its late-stage depression program and a successful capital raise. • The APPROACH Phase 3...
🟢 Cybin is trading 6.6% up today on Phase 3 depression trial progress and $50M equity raise
Cybin is trading 6.6% up at $7.58 in pre-market, extending gains driven by optimism around its late-stage depression program. • The company surpassed 86%...
🟢 Cybin is trading 5.4% up today on Phase 3 progress and reinforced cash position
Cybin is trading 5.4% up at $7.64 in pre-market, extending last week’s strong gains as investors react to positive clinical developments and a strengthened...
Cybin Jumps 8% on Wall Street Cheerleading, but Can a Pre-Revenue Psychedelic Biotech Justify a $38 Price Target?
Shares shifted as Cybin Inc. — now operating as Helus Pharma (HELP) — surged 7.8% to $7.02 on bullish analyst coverage emphasizing the company's cash reserves...
🟢 Cybin is trading 12.4% up
Cybin is trading at $7.32, up 12.4% from a comparison close of $6.51 during regular trading. This is a price-action follow-up, so a separate catalyst may not...
🟢 Cybin is trading 8% up today on bullish analyst coverage and cash-position optimism
Cybin is trading 8% up today at $7.02 following upbeat analyst commentary and growing optimism regarding its cash position. • Analysts have issued multiple...
🟢 Cybin is trading 12.4% up today on bullish analyst coverage and a reinforced balance sheet
Cybin is trading 12.4% up at $7.32 in pre-market following bullish analyst coverage and commentary regarding its strengthened cash position. • Analysts cited...
🟢 Cybin is trading 9.8% up today on bullish analyst coverage and reinforced balance sheet
Cybin is trading at $7.15 (9.8%) up in pre-market following bullish analyst coverage and commentary regarding its reinforced balance sheet. • Analysts...
🟢 Cybin is trading 4.6% up today on bullish analyst coverage and a reinforced balance sheet
Cybin is trading 4.6% up at $6.81 following positive analyst sentiment and reports of a reinforced balance sheet. • Analysts highlighted clinical progress and...
🟢 Cybin is trading 12.1% up today on bullish analyst coverage and reinforced balance sheet
Cybin is trading 12.1% up at $7.30 in pre-market, extending recent strength driven by upbeat analyst coverage and a reinforced balance sheet. • Guggenheim...
🔴 Cybin is trading 5.2% down today amid a broader biotech pullback and risk-off market sentiment
Cybin is trading at $6.51 (-5.23%) as the stock faces pressure from a broader biotech sector selloff and a weaker overall market tone. • The decline aligns...
🟢 Cybin is trading 5.5% up today as it extends its multi-day rally
Cybin is trading 5.5% up at $6.57 as the stock extends its recent multi-day rally despite a lack of fresh company-specific news. • The upward move appears...
🟢 HELP is trading 5.8% up today as momentum continues with no clear catalyst
HELP is trading 5.8% up at $6.38 in pre-market, extending recent gains in the absence of new company-specific catalysts. • The stock is building on a 2.4%...
🟢 HELP is trading 5.02% up today on financing and pipeline momentum
HELP is trading 5.02% up at $6.80 following Cybin’s recent financing and pipeline momentum. • The move is largely attributed to the company's $50 million...
Cybin Inc. Q1 2026 Earnings Preview: What Analysts Expect on June 29, 2026
Analysts expect Cybin Inc. to report a consensus EPS loss of $1.04 on zero revenue, with the stock currently priced at $4.85 compared to a $49.05 average...
🟢 HELP is trading 5.15% up today after closing a $50M offering for Phase 3 trials
HELP is trading 5.15% up at $6.33 after Cybin/Helus Pharma closed a $50 million share offering to fund late-stage depression-trial work. • The capital...
Helus Pharma Secures $50 Million, Funding Phase 3 Depression Trials
Helus Pharma, the operating name for Cybin Inc., closed its public offering of 10,309,280 common shares. The company sold the shares at US$4.85 each to raise...
🔴 HELP is trading 6.2% down today after a $50 million equity offering and recent rally
HELP is trading 6.2% down at $5.65 in pre-market following a $50 million underwritten equity offering and profit-taking after a sharp multi-day rally. • The...